The Victor Babeș University of Medicine and Pharmacy, Timișoara (Romanian: Universitatea de Medicină și Farmacie "Victor Babeș", or UMF Timișoara) is located in Timișoara, Romania. It was named in honor of the scientist Victor Babeș.
Purpose The persistent proatlantal artery represents persistence of the embryonic first cervical intersegmental artery and creates a carotid-vertebral anastomosis. A persisting carotid duct is an exceptionally rare persistence of the dorsal aortic segment between the third and fourth aortic arches. It may be associated with segmental occlusion/stenosis of the proximal external carotid artery. Methods Archived computed tomography angiography files in a 62 year-old man were studied anatomically. Results A right-sided persisting carotid duct arising from the subclavian artery with short proximal ECA occlusion/stenosis and reconstitution of the distal ECA was found. A large type II PPA arose from the reconstituted ECA, formed a suboccipital loop giving rise to the occipital segment of the occipital artery, and established two distinct junctions with the vertebral artery: an anterior branch to the V3 segment near the posterior condylar foramen and an inferior branch to the V2 segment immediately before entry into the C1 transverse foramen. Conclusion This configuration provides imaging evidence of a true 'double-connection' of a persisting proatlantal artery, coexisting with a persisting carotid duct and proximal external carotid occlusion/stenosis, with potential implications for carotid interventions and posterior-circulation haemodynamics.
This review addresses the escalating global water crisis driven by water pollution, especially by heavy metal ions, a consequence of rapid industrialization and population growth. Due to their high toxicity, solubility, and persistence, heavy metals pose a severe threat to human health and ecosystems through bioaccumulation. The analysis highlights a strategic shift in wastewater management from simple elimination of the toxics metal ions to the recovery of metal ions with economic value. Given the increasing complexity of industrial effluents, the scientific community is intensifying its focus on evaluating the technical and financial feasibility of various treatment technologies. Significant research is being conducted to address these environmental issues, and innovative technologies are being developed to enhance the quality of water contaminated by metal ions. On the other hand, to prevent pollution, plans containing several barriers must be established, including management, economic, and technical ones. Ultimately, the reuse of treated wastewater is the only viable long-term solution for securing global drinking water supplies. A new analysis focused on the transition from traditional, inefficient, and costly wastewater treatment to advanced, resource recovery-oriented systems is essential. The current perspective shows a clear need to advance beyond synthetic laboratory studies to real-world applications while addressing operational barriers to support a circular economy based on simple disposal of the toxic metal ions to the recovery of metals with economic value (e.g., copper, gold, silver, rare metals). Also, although the field has been explored, a new review is imperative because current technologies that show high efficiency (up to 99%) in the removal of toxic metal ions (adsorption, membrane filtration, electrochemical processes) face major challenges, such as the formation of large volumes of toxic sludge, membrane fouling, and high operating costs.
Background/Objectives: Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide well-established cardiovascular and renal benefits in heart failure (HF), type 2 diabetes (T2DM), and chronic kidney disease (CKD). Although emerging trials suggest potential value after acute myocardial infarction (AMI), SGLT2 inhibitors currently have no formal indication for AMI, and real-world prescribing patterns in this setting remain uncharacterized. This study aimed to evaluate in-hospital and post-discharge prescribing patterns and clinical predictors of SGLT2 inhibitor initiation among AMI patients eligible for therapy based on guideline-supported indications. Methods: We conducted a retrospective cohort study including 244 consecutive AMI patients hospitalized between January 2023 and July 2024. A total of 180 (73.7%) met guideline-based eligibility criteria for SGLT2 inhibitors. Four multivariable logistic regression models were developed to identify independent predictors of SGLT2 inhibitor prescription. Results: A total of 117 patients (65%) received SGLT2 inhibitors and 63 (35%) remained untreated. Receivers were more frequently male (81% vs. 65%) and exhibited lower left ventricular ejection fraction (LVEF) (38.2 ± 6.7% vs. 42.4 ± 8.3%), larger ventricular volumes, and higher Killip class at presentation. HF patients with preserved ejection fraction (HFpEF) were markedly undertreated (25.9%) compared with mid-range (HFmrEF) (69.8%) or reduced (HFrEF) (73.7%). Across all models, HFpEF was a strong negative predictor of prescribing (OR 0.071-0.081, p < 0.001), while male sex and markers of clinical severity were associated with higher likelihood of initiation. Many untreated patients had T2DM or CKD despite guideline-based eligibility. No serious adverse events attributable to SGLT2 inhibitors were reported. Conclusions: In this real-world AMI cohort, SGLT2 inhibitors were prescribed primarily in relation to established indications for HF, T2DM, and CKD, yet their use remained highly variable in the absence of a dedicated recommendation for AMI. Significant therapeutic gaps were observed in HFpEF and high-risk cardiometabolic profiles, underscoring the need for clearer guidance and standardized pathways to support consistent initiation in eligible patients after MI.
Climate variability plays a crucial role in shaping drinking water quality, yet the quantitative links between meteorological factors and microbiological contamination remain underexplored in temperate continental climates. A secondary data analysis was conducted on 15,394 microbiological water quality test results collected between 2015 and 2024, including heterotrophic plate counts (22 °C and 37 °C), coliform bacteria, and Escherichia coli, and their associations with local meteorological conditions across groundwater wells and piped distribution networks were examined. A clear distinction emerged: groundwater wells showed higher vulnerability to primary microbial contamination (coliforms and E. coli), whereas distribution networks exhibited higher odds of heterotrophic plate count exceedances, indicating greater susceptibility to post-treatment microbial regrowth. In groundwater wells, temperature showed strong positive associations with all microbial indicators (p < 0.001), with pronounced summer peaks in coliforms and E. coli, while precipitation triggered short-term contamination spikes characterized by a 2-day lag. In contrast, piped networks exhibited weaker and more delayed meteorological responses. These results highlight the need for a shift from climate-responsive to climate-pre-emptive water quality monitoring by incorporating meteorological forecasts, especially for non-chlorinated groundwater sources.
Predicting disease progression at the individual level is essential for personalized medicine. We previously developed machine-learning tools to estimate 5-year progression risk in people with multiple sclerosis (PwMS). Such models should account for disease-modifying therapy (DMT) and objective outcome definitions. In a retrospective multicenter case–control study, we evaluated adults with relapsing–remitting multiple sclerosis (RRMS) at baseline. Using machine-learning, we developed two complementary tools for individualized 5-year risk estimation: DAAE-M, optimized for transparency, software-neutral use, and mitigation of indication bias, and ELIE, optimized for dynamic landmark-based modeling, complex treatment histories, and mitigation of immortal-time bias. Disease progression was defined using both a clinical outcome (RRMS-to-progressive MS) and an objective outcome (late-stage confirmed progression independent of relapse activity). Among 34,510 people with RRMS (72.6